INTRODUCTION

This article aims to comprehensively review the impact of bariatric surgery on diabetic retinopathy (DR), a microvascular complication of type 2 diabetes mellitus (T2DM). Initially, an overview of epidemiology, classification, and pathogenesis of DR is presented. The relative benefits of medical and surgical treatment on glycemic control in T2DM are then briefly discussed. Following on from this the impact of medical management of hyperglycemia on DR is discussed, highlighting concerns about the effect of rapid reductions in blood glucose levels. Finally, the current evidence relating to the impact of bariatric surgery on DR in both the short- and long-term is discussed in detail.

DIABETIC RETINOPATHY-EPIDEMIOLOGY AND CLASSIFICATION

DR is the most common microvascular complication of T2DM worldwide and the leading cause of visual impairment among adults aged 20 to 74, with approximately 93 million people currently living with DR [12]. According to data from the United Kingdom Prospective Diabetes Study (UKPDS), 37% of patients with T2DM have evidence of retinopathy at the time of diagnosis [3]. After two decades of disease, >60% of patients with T2DM are expected to have some degree of retinopathy [4]. The principal risk factors for DR are degree and duration of hyperglycemia and the presence of comorbid hypertension with or without dyslipidemia [2]. DR is classified as non-proliferative diabetic retinopathy (NPDR) and proliferative diabetic retinopathy (PDR) disease with reference to events occurring in the retinal capillary bed. DR is usually assessed using fundoscopic examiniation of a dilated pupil and retinal images can be recorded for future evaluation. Clinical evaluation in most centers is based on the Early Treatment Diabetic Retinopathy Study (ETDRS) grading scheme [5].

A SUMMARY OF PATHOGENIC MECHANISMS

Early DR is usually asymptomatic but this belies structural and functional changes in the capillaries and supporting pericytes, which cause microvessel aneurysm, occlusion and leakiness and the onset of hypoxic injury. Pericytes are perivascular contractile cells that aid in the stabilization and maturation of endothelial cells. Pericyte loss is a hallmark of early DR and typically precedes endothelial cell loss [6]. Hypoxic stimuli trigger the formation of abnormally branched or dilated retinal vessels termed intraretinal microvascular abnormalities (IRMAs) in NPDR, and neovascularization in PDR [7]. Typically, neovascularization arises at the junction of nonperfused vessels and leaky vessels and at the optic disk, and can spread through the inner limiting membrane into the vitreous humor. These vessels exhibit increased permeability, raising the risk of vascular leakage and vitreous haemorrhage. Vessel permeability can result in diabetic macular edema (DME). DME, present in up to 25% of people with diabetes, presents with progressive impairment of visual acuity [8]. A fibrous component develops with neovascularization, increasing the risk of tractional retinal detachment [8]. Lipid deposition at the edges of small haemorrhages creates hard exudates, which contribute to microcystoid degeneration of the retina [9].

Microvascular injury and neurodegenerative effects of hyperglycemia are considered to be central events in the development of DR in cases of chronically poor control of T2DM [1011]. Hyperglycemia accelerates advanced glycation end products (AGE) formation. AGEs cross–link with proteins in the extracellular matrix, decreasing protein removal and enhancing deposition [12]. Activation of the AGE receptor results in the release of proinflammatory cytokines and growth factors, increased oxidative stress, procoagulant activity on endothelial cells and macrophages, proliferation of vascular smooth muscle cells and increased extracellular matrix synthesis [10]. Activation of the protein kinase C pathway leads to the upregulation of vascular endothelial growth factor [13] and increased production of profibrogenic molecules involved in basement membrane synthesis. Cellular sorbitol accumulation increases osmotic stress, contributing to vascular damage [14]. Nicotinamide adenine dinucleotide phosphate consumption in the polyol pathway increases the susceptibility of cells to oxidative stress [1]. During hyperglycemia excess glycolytic fructose-6-phosphate is directed through the overflow hexosamine biosynthesis pathway, the end product of which causes aberrant posttranslational modification of cytosolic and nucleic proteins. This results in the increased expression of transforming growth factor β1 and plasminogen activator inhibitor-1, adversely affecting endothelial cells [15]. Progressive microvascular injury promotes inflammation in the retina involving microglial activation and macrophage infiltration into the neural retina [8].

The constellation of pathogenic effects of hyperglycemia in the retina may be ameliorated by intensified therapies for T2DM. The relative impact of intensive medical and surgical interventions on control of diabetes and DR is described below.

CONTROL OF T2DM-RELATIVE EFFICACY OF MEDICAL AND SURGICAL APPROACHES

Medical management has traditionally been the mainstay of T2DM treatment. However bariatric surgery, originally intended as a weight-loss procedure for very severely obese individuals (body mass index [BMI] >40 kg/m²), has beneficial effects on glycemic control in obese patients with T2DM [161718]. Typically, successful bariatric surgery results in a >30% reduction in total body weight within 1 year, making it the most effective treatment for weight loss [19].

Several randomized controlled trials (RCTs) and large case control, studies have additionally shown that bariatric procedures are superior to standard lifestyle intervention and pharmacological therapy for treatment of T2DM in obese patients [161718202122]. Though these effects are not permanent, they are long lasting and when relapse occurs, good metabolic control can be achieved with relatively low intensity medical interventions

MEDICAL MANAGEMENT: LONG-TERM EFFECTS ON DIABETIC RETINOPATHY

Several studies comparing the effect of intensified glycemic control to standard treatment for T2DM have included secondary endpoints that focus on ophthalmic outcomes. These studies are summarized in Table 1. The UKPDS is a large RCT comparing intensive and conventional glycemic control in patients with newly diagnosed T2DM. After 10 years, the intensive treatment cohort achieved a glycosylated hemoglobin (HbA1c) of 7.0% compared to 7.9% in the conventional treatment group. The risk of progression of retinopathy was reduced by 21% in the intensive treatment group after 12 years (n=718). The UKPDS group concluded that for every 1% decrease in HbA1c, the relative risk of developing microvascular complications decreased by 35% [23]. The Kumamoto study is a smaller study comprising of 110 Japanese patients with T2DM. Participants had no DR or mild NPDR at baseline and were randomized to intensive or conventional insulin therapy. After 8 years, this study found that the combined risk reduction for both the development and progression of DR with intensive treatment was 63% [24].

In the Action in Diabetes and Vascular Disease Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) RCT, participants were randomised to an intensive glycaemic control target HbA1c of 47.5 mmol/mol (6.5%) or a standard care target of 53 mmol/mol (7%). At the start of the study the participants had a mean duration of T2DM of 6 years. After 4 years, no significant difference in incidence and progression of DR was observed between groups (n=1,241) [25]. Progression of DR was evaluated in the glycemic control arm of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial (n=2,856). Participants had a mean duration of T2DM of 10 years at study entry. Intensive glycaemic control targeted an HbA1c of 42 mmol/mol (6%), lower than other studies. After 4 years, retinopathy progression occurred in 7.3% of the intensive treatment group compared to 10.4% of the standard therapy group [26]. The Veteran's Administration Diabetes Trial (VADT) studied 1,792 patients who had a mean duration of T2DM of 11.5 years. After a mean follow-up of 5.6 years, HbA1c was 8.4% in the standard therapy cohort compared to 6.9% in the intensive therapy cohort. There was a nonsignificant trend suggesting beneficial effect with intensive-therapy as the increase in DR severity was greater in the standard-therapy group (P=0.07). However, there were no differences between groups in the incidence of new onset DR or in progression to PDR or clinically relevant DME [27].

MEDICAL MANAGEMENT: CONCERNS OVER RAPID IMPROVEMENT IN HYPERGLYCEMIA

Although overall improvements in glycemic control are associated with reduced development and progression of DR in the long-term, initial worsening of DR has been reported as a consequence of rapid improvement of hyperglycemia. Without any change in blood glucose levels, the risk of progression from severe NPDR or early PDR to high-risk severe PDR is approximately 25% over 4 to 6 months. This risk may increase to 50% with intensive glucose-lowering treatment [28].

Initiation of treatment in patients with type 1 diabetes mellitus resulting in a substantial decrease in HbA1c has been associated with the development of severe retinopathy, vitreous haemorrhage or macular edema within 1 year in patients who had little or no retinopathy at baseline [29]. The Diabetes Control and Complications Trial (DCCT) documented the phenomenon of transient, early worsening of DR with intensive glycemic control (n=1,439). At 6, 12, and 18 months progression by three steps or more on the ETDRS retinopathy scale was more common with intensive treatment. The 13.1% of the intensive group and 7.6% of the conventional group experienced 'early worsening,' defined as the development of soft exudates, IRMAs, or clinically important retinopathy within the first 12 months. Approximately half of these patients had recovered at the 18-month follow-up. The magnitude of the decrease in HbA1c in the first 6 months of treatment was the most important risk factor for early worsening. Each percentage point drop in HbA1c is associated with a 1.6 times increase risk of early worsening. Severity of retinopathy at baseline is also associated with the risk of worsening [30]. Proposed mechanisms for this phenomenon include a decrease in the availability of nutrient substrate, a reduction in the ability of retinal circulation to autoregulate and also in increase in growth factors [3031323334]. Unfortunately, a similar trial has not been conducted in T2DM. However, Henricsson et al. [35] did find a relationship between the degree of HbA1c improvement and deterioration of DR in insulin-treated patients with T2DM (n=45) over a 2-year period. This paradoxical deterioration of retinal function with improved glycemic control has also been observed with intensified insulin treatment in pregnancy. The deterioration of background retinopathy correlated with the magnitude of glycemic control [36]. In a retrospective 1 year study of 165 patients treated with glucagon-like peptide-1 (GLP-1) receptor agonist (exenatide), overall 29.7% of patients treated had new or worsening DR while 19.4% of the cohort showed an improvement in pre-existing DR. Interestingly there was a significant difference in DR progression rates between those patients with an improved HbA1c profile (35.3% progression rate) versus those in whom HbA1c profile deteriorated (6.2% progression rate) [37]. The recently published Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) RCT examined prospectively, with a mean follow-up of 3.8 years, the longer-term effects of treatment with a GLP-1 analogue on DR. This showed no significant impact the incidence of DR (hazard ratio, 1.15; 95% confidence interval, 0.87 to 1.52), despite evidence of a significant reduction in nephropathy [38].

Despite reports of early worsening, the beneficial effects of intensive glycemic control are substantial in the long term. By inference, this apparently contradictory data is suggestive of longer-term adaptation of the retina to lower glycemic levels. In the brain, adaptation to hypoglycemia occurs via up-regulation of glucose transporter 1 (GLUT1), a glucose transporter protein, and it may be speculated that an analogous phenomenon may be implicated in long-term adaptation in the retina [39].

SURGICAL MANAGEMENT OF T2DM AND DR OUTCOMES

Since 2012, data has been emerging on the effect of bariatric surgery on DR. Data was collected following systematic interrogation of PubMed using the following terms: "bariatric surgery," "Roux-en-Y gastric bypass," "gastric bypass," "bilio-pancreatic diversion," "gastric band," "vertical sleeve gastrectomy," and "diabetic retinopathy." This strategy generated 36 results and after removal of duplicates, review articles, anecdotal case reports, and letters, 13 relevant studies remained. These studies are included in the following section and are summarised in Table 2.

SURGICAL MANAGEMENT: SHORT TERM OUTCOMES

Changes in DR are unpredictable following bariatric surgery. Given the reported impact on DR of rapid correction of glycemic control using pharmacological approaches, concerns have been raised about the rapid and substantial decreases in blood glucose levels that occur after bariatric procedures. Concerns also exist about the detrimental effects of episodes of postoperative reactive hypoglycemia [40]. A number of studies investigating the effect of bariatric surgery on retinal outcomes in patients with T2DM and obesity have been carried out. In the Mannheim obesity study (n=30) in 2012, the arteriole-to-venule ratio, a marker of retinal inflammation/endothelial dysfunction, improved significantly in obese patients with cardiovascular risk factors at 9 months postbariatric surgery [41].

Varadhan et al. [42] conducted a small, retrospective, pilot study in 2012 to investigate to effect of vertical sleeve gastrectomy (VSG) or Roux-en-Y gastric bypass (RYGB). Retinal images were taken presurgery and from 6 to 12 months after surgery. Of those without preoperative DR (n=15), two developed new DR. Of those with preoperative DR (n=7), two progressed, two regressed and three remained stable. Despite the small numbers included (n=22), considering 18% of patients developed new DR or experienced deterioration of their existing DR, this pilot study identified the need for further investigation into the implication of bariatric surgery on ophthalmic outcomes [42].

A retrospective study with a mean follow up of 1 year was conducted by Miras et al. [43] in 2012 (n=67). The main effect observed overall was stabilization (91%). A significant improvement was observed in a subgroup that had established preoperative DR, with 17.8% improving and 3.6% deteriorating [43].

Johnson et al. [44] conducted a large retrospective study in 2013 (n=15,951). Less ophthalmic manifestations, defined as new diagnosis of blindness in ≥1 eye/laser eye or retinal surgery, were reported in the bariatric surgery group (<0.1%/0.2%) than in the non-surgical group (0.3%/0/6%) after a follow-up of less than 2 years. However caution should be taken when interpreting these results as the endpoints examined are rare and very severe [44].

Thomas et al. [45] conducted a 12-month retrospective pilot analysis in 2014 (n=40). Of those without preoperative DR (n=26), 22 still had no evidence of DR postsurgery. The remaining four developed minimum background diabetic retinopathy (BDR). Five out of nine participants with minimum BDR before surgery deteriorated, while the other four did not change. The only participant with moderately severe BDR (n=1) progressed to preproliferative diabetic retinopathy (PPDR). Two of those with PPDR (n=4) before surgery deteriorated, with the other two lost to follow-up [45].

In 2015, Amin et al. [46] conducted a retrospective cohort study (n=152) with a mean follow-up duration of 3 years. Results revealed that the risk of developing sight-threatening DR was lower after bariatric surgery (5.7%) compared to non-surgical management (12.1%). However, the absence of evidence of DR prior to surgery did not eliminate the risk of developing sight-threatening diabetic retinopathy postoperatively [46].

A retrospective case-control study carried out by Miras et al. [47] in 2015 revealed that after 1 year there were no significant differences in retinal outcomes in participants who underwent RYGB compared to medical treatment. In the surgical cohort (n=56), 44 participants experienced no change, six improved, and six deteriorated. In the medical group (n=21), 17 patients experienced no change, one improved, and three deteriorated [47].

In 2015, a retrospective observational study conducted by Murphy et al. [48] (n=318) revealed that 73% of patients undergoing bariatric surgery had no change in their retinopathy grade after a mean of 334 days, a moderate or higher-grade retinopathy postoperatively was associated with the magnitude of HbA1c reduction, a higher preoperative retinopathy grade and male gender.

A small pilot study carried out by Kim et al. [49] in 2015 (n=20) identified that two out of 12 participants without preoperative DR and two out of three participants with mild NPDR developed moderate NPDR after surgery. All five participants who had moderate NPDR preoperatively experienced progression that required further intervention. Although 30% of participants who underwent surgery entered remission of T2DM, the risk of progression of DR was not eliminated in this cohort [49].

Banks et al. [50] conducted a retrospective case-control pilot study investigating the progression of DR after RYGB (n=21) compared to medical therapy (n=24). DR progressed significantly in the medical therapy group, but not in the RYGB group. However, there was no significant difference when the change in DR scores was compared between groups. Results from this study were inconclusive due to heterogeneity of group characteristics [50].

Brynskov et al. [51] conducted a prospective observational study of patients undergoing RYGB or VSG (n=56). Overall, six patients experienced worsening of DR at any time within 1 year, but this only persisted in three patients at 12 months. In patients with preoperative DR (n=24), 17 participants experienced no change, three deteriorated, and four improved. For those without preoperative DR, one out of 30 participants experienced a transient worsening at 6 months, but at 12 months all 30 were unchanged from baseline. This study concluded that retinopathy was clinically stable in the first year after bariatric surgery [51].

The Surgical Therapy And Medications Potentially Eradicate Diabetes Efficiently (STAMPEDE) RCT was the first study that compared the effects of intensive medical management to bariatric surgery on DR in a large population of patients with T2DM (n=150). After 2 years, this study found that RYGB/VSG did not significantly impact DR. Of all participants, surgical and medical, 86.5% experienced no change in their retinopathy scoring postoperatively [52].

There is significant heterogeneity in the data relating to the shorter term impact of bariatric surgery on DR. Some of the variability in the data may be explained by differences in the incidence of hypoglycaemia, a phenomenon not systematically tracked after surgery, or by the type of bariatric procedure performed.

SURGICAL MANAGEMENT: LONG-TERM OUTCOMES

There is a paucity of data on the long-term effects of bariatric surgery on DR. A retrospective analysis with a 13-year follow-up, focusing on the effects of laparoscopic adjustable gastric band (LABG) in morbidly obese patients (BMI ≥35 kg/m²), with or without diabetes, was carried out by Zakaria et al. [53]. Despite the long follow-up, no new cases of DR were recorded in the LABG group (n=87) compared with a single case in the control goup (n=87). These results indicate that LABG is not associated with an increased risk of DR and that outcomes are similar to medical treatment in the long term [53].

Abbatini et al. [54], evaluated the long-term effects of VSG on T2DM severely obese patients retrospectively. Thirty-three patients had a 3-year follow-up and 13 of these were also followed up at 5 years. No new incidences of DR were reported, supporting the concept of bariatric surgery having a preventative effect on DR development. The single case of preoperative DR had not progressed when assessed at the 3-year follow-up point [54].

The Swedish Obese Subjects study did reveal that bariatric surgery was associated with a decrease in the incidence of microvascular complications compared to medical treatment. After a mean follow-up of 17.6 years, the incidence in the non-surgical cohort (n=55) was 41.8 per 1,000 person-years compared to 20.6 per 1,000 person-years in the surgery cohort (n=288). Unfortunately the composite end-point incorporated renal, retinal and neural endpoints, including whichever complication occurred first. Therefore, it was not possible to specify the effect of surgical intervention on retinal outcomes in this long-term study [17].

CONCLUSIONS

The current evidence suggests that the risk of progression of pre-existing DR or the development of new DR are not eliminated by bariatric surgery or by the remission of T2DM and that surgical intervention may be more beneficial at an earlier stage of disease development. In the literature, the majority of patients with established DR at the time of surgery had no change in their DR grade after surgery. However, instances of regression and progression have also been recorded [42434445464849505152535455]. This trend was also observed in a systematic review and meta-analysis by Cheung et al. [56] that comprised of four primary studies (n=148). Raw data was sought from all relevant studies. In Table 3, data that was successfully obtained was collapsed to determine the number of cases that deteriorated, improved or remained stable depending on DR status at baseline. Possible risk factors for progression of DR include severity of DR at time of surgery and the magnitude of the reduction of HbA1c.

The retina is one of the most metabolically active tissues in the body. Neural tissue is solely dependent on glucose for energy rendering the retina more vulnerable than the kidney to periods of hypoglycemia. Concerns remain over the effect of the rapid decrease of HbA1c after surgery on retinal outcomes. This rapid correction of blood glucose, along with postsurgical reactive hypoglycemia potentially contributes to worsening of DR.

Avoiding postprandial hypoglycemia may prevent hypoglycemia detracting from the beneficial effect of removal of hyperglycemia. Deepening our understanding of the complex pathophysiology of postprandial hypoglycemia after bariatric surgery and optimizing appropriate therapy may prove crucial in improving retinal outcomes.

The data on DR are thus much less coherent than the picture developing with regard to diabetic kidney disease (DKD). Bariatric surgery is uniformly associated with a reduction in urinary albumin excretion, leading indicating improvement in DKD [57]. Parity of the measurements available for DKD is not achievable clinically for DR. Therefore, in-depth animal studies comparing chronology of DR progression and the impact of surgery could provide clarity on the situation. However, for now, whether the effect of bariatric surgery on DR is good, bad or both remains inconclusive.

Acknowledgements

ACKNOWLEDGMENTS

D.M. Gorman is an intercalated M.Sc student from the University College Dublin medical degree programme (MB BCh BAO). Work in the group on microvascular complications of diabetes is supported by a Science Foundation Ireland President of Ireland Young Researcher Award to C.W. le Roux (12/YI/B2480). C.W. le Roux (PI) and N.G. Docherty are co-investigators on a grant from the Swedish Research Council (Medicine and Health) (2015-02733).

NOTES

CONFLICTS OF INTEREST: No potential conflict of interest relevant to this article was reported.

REFERENCES

• 1. Forbes JM, Cooper ME. Mechanisms of diabetic complications. Physiol Rev 2013;93:137-188. ArticlePubMed
• 2. Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, Chen SJ, Dekker JM, Fletcher A, Grauslund J, Haffner S, Hamman RF, Ikram MK, Kayama T, Klein BE, Klein R, Krishnaiah S, Mayurasakorn K, O'Hare JP, Orchard TJ, Porta M, Rema M, Roy MS, Sharma T, Shaw J, Taylor H, Tielsch JM, Varma R, Wang JJ, Wang N, West S, Xu L, Yasuda M, Zhang X, Mitchell P, Wong TY. Meta-Analysis for Eye Disease (META-EYE) Study Group. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 2012;35:556-564. ArticlePubMedPMCPDF
• 3. Stratton IM, Kohner EM, Aldington SJ, Turner RC, Holman RR, Manley SE, Matthews DR. UKPDS 50: risk factors for incidence and progression of retinopathy in type II diabetes over 6 years from diagnosis. Diabetologia 2001;44:156-163. ArticlePubMedPDF
• 4. Fong DS, Aiello L, Gardner TW, King GL, Blankenship G, Cavallerano JD, Ferris FL 3rd, Klein R. American Diabetes Association. Retinopathy in diabetes. Diabetes Care 2004;27(Suppl 1):S84-S87. ArticlePubMedPDF
• 5. Heng LZ, Comyn O, Peto T, Tadros C, Ng E, Sivaprasad S, Hykin PG. Diabetic retinopathy: pathogenesis, clinical grading, management and future developments. Diabet Med 2013;30:640-650. ArticlePubMed
• 6. Ciulla TA, Amador AG, Zinman B. Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies. Diabetes Care 2003;26:2653-2664. PubMed
• 7. Moreno A, Lozano M, Salinas P. Diabetic retinopathy. Nutr Hosp 2013;28(Suppl 2):53-56. PubMed
• 8. Antonetti DA, Klein R, Gardner TW. Diabetic retinopathy. N Engl J Med 2012;366:1227-1239. ArticlePubMed
• 9. Gandorfer A, Rohleder M, Grosselfinger S, Haritoglou C, Ulbig M, Kampik A. Epiretinal pathology of diffuse diabetic macular edema associated with vitreomacular traction. Am J Ophthalmol 2005;139:638-652. ArticlePubMed
• 10. Sena CM, Pereira AM, Seica R. Endothelial dysfunction: a major mediator of diabetic vascular disease. Biochim Biophys Acta 2013;1832:2216-2231. ArticlePubMed
• 11. Villarroel M, Ciudin A, Hernandez C, Simo R. Neurodegeneration: an early event of diabetic retinopathy. World J Diabetes 2010;1:57-64. ArticlePubMedPMC
• 12. Sharma Y, Saxena S, Mishra A, Saxena A, Natu SM. Advanced glycation end products and diabetic retinopathy. J Ocul Biol Dis Infor 2013;5:63-69. ArticlePubMedPMCPDF
• 13. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005;54:1615-1625. PubMed
• 14. Fowler MJ. Microvascular and macrovascular complications of diabetes. Clin Diabetes 2008;26:77-82.ArticlePDF
• 15. Du XL, Edelstein D, Rossetti L, Fantus IG, Goldberg H, Ziyadeh F, Wu J, Brownlee M. Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc Natl Acad Sci U S A 2000;97:12222-12226. ArticlePubMedPMC
• 16. Mingrone G, Panunzi S, De Gaetano A, Guidone C, Iaconelli A, Nanni G, Castagneto M, Bornstein S, Rubino F. Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial. Lancet 2015;386:964-973. ArticlePubMed
• 17. Sjostrom L, Peltonen M, Jacobson P, Ahlin S, Andersson-Assarsson J, Anveden A, Bouchard C, Carlsson B, Karason K, Lonroth H, Naslund I, Sjostrom E, Taube M, Wedel H, Svensson PA, Sjoholm K, Carlsson LM. Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. JAMA 2014;311:2297-2304. ArticlePubMed
• 18. Schauer PR, Bhatt DL, Kirwan JP, Wolski K, Brethauer SA, Navaneethan SD, Aminian A, Pothier CE, Kim ES, Nissen SE, Kashyap SR. STAMPEDE Investigators. Bariatric surgery versus intensive medical therapy for diabetes: 3-year outcomes. N Engl J Med 2014;370:2002-2013. ArticlePubMedPMC
• 19. Docherty NG, Canney AL, le Roux CW. Weight loss interventions and progression of diabetic kidney disease. Curr Diab Rep 2015;15:55ArticlePubMedPDF
• 20. Courcoulas AP, Goodpaster BH, Eagleton JK, Belle SH, Kalarchian MA, Lang W, Toledo FG, Jakicic JM. Surgical vs medical treatments for type 2 diabetes mellitus: a randomized clinical trial. JAMA Surg 2014;149:707-715. ArticlePubMedPMC
• 21. Ikramuddin S, Korner J, Lee WJ, Connett JE, Inabnet WB, Billington CJ, Thomas AJ, Leslie DB, Chong K, Jeffery RW, Ahmed L, Vella A, Chuang LM, Bessler M, Sarr MG, Swain JM, Laqua P, Jensen MD, Bantle JP. Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: the Diabetes Surgery Study randomized clinical trial. JAMA 2013;309:2240-2249. ArticlePubMedPMC
• 22. Liang Z, Wu Q, Chen B, Yu P, Zhao H, Ouyang X. Effect of laparoscopic Roux-en-Y gastric bypass surgery on type 2 diabetes mellitus with hypertension: a randomized controlled trial. Diabetes Res Clin Pract 2013;101:50-56. ArticlePubMed
• 23. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853. ArticlePubMed
• 24. Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000;23(Suppl 2):B21-B29. PubMed
• 25. Beulens JW, Patel A, Vingerling JR, Cruickshank JK, Hughes AD, Stanton A, Lu J, McG Thom SA, Grobbee DE, Stolk RP. AdRem project team. ADVANCE management committee. Effects of blood pressure lowering and intensive glucose control on the incidence and progression of retinopathy in patients with type 2 diabetes mellitus: a randomised controlled trial. Diabetologia 2009;52:2027-2036. ArticlePubMedPDF
• 26. ACCORD Study Group. ACCORD Eye Study Group. Chew EY, Ambrosius WT, Davis MD, Danis RP, Gangaputra S, Greven CM, Hubbard L, Esser BA, Lovato JF, Perdue LH, Goff DC Jr, Cushman WC, Ginsberg HN, Elam MB, Genuth S, Gerstein HC, Schubart U, Fine LJ. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010;363:233-244. ArticlePubMedPMC
• 27. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD. VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129-139. ArticlePubMed
• 28. Davis MD. Diabetic retinopathy. A clinical overview. Diabetes Care 1992;15:1844-1874. ArticlePubMedPDF
• 29. Moskalets E, Galstyan G, Starostina E, Antsiferov M, Chantelau E. Association of blindness to intensification of glycemic control in insulin-dependent diabetes mellitus. J Diabetes Complications 1994;8:45-50. ArticlePubMed
• 30. The Diabetes Control and Complications Trial Research Group. Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. Arch Ophthalmol 1998;116:874-886. ArticlePubMed
• 31. Dahl-Jorgensen K, Brinchmann-Hansen O, Hanssen KF, Sandvik L, Aagenaes O. Rapid tightening of blood glucose control leads to transient deterioration of retinopathy in insulin dependent diabetes mellitus: the Oslo study. Br Med J (Clin Res Ed) 1985;290:811-815.ArticlePubMedPMC
• 32. Grunwald JE, Brucker AJ, Schwartz SS, Braunstein SN, Baker L, Petrig BL, Riva CE. Diabetic glycemic control and retinal blood flow. Diabetes 1990;39:602-607. ArticlePubMed
• 33. Ernest JT, Goldstick TK, Engerman RL. Hyperglycemia impairs retinal oxygen autoregulation in normal and diabetic dogs. Invest Ophthalmol Vis Sci 1983;24:985-989. PubMed
• 34. Merimee TJ, Zapf J, Froesch ER. Insulin-like growth factors. Studies in diabetics with and without retinopathy. N Engl J Med 1983;309:527-530. ArticlePubMed
• 35. Henricsson M, Berntorp K, Berntorp E, Fernlund P, Sundkvist G. Progression of retinopathy after improved metabolic control in type 2 diabetic patients. Relation to IGF-1 and hemostatic variables. Diabetes Care 1999;22:1944-1949. ArticlePubMedPDF
• 36. Phelps RL, Sakol P, Metzger BE, Jampol LM, Freinkel N. Changes in diabetic retinopathy during pregnancy. Correlations with regulation of hyperglycemia. Arch Ophthalmol 1986;104:1806-1810. ArticlePubMed
• 37. Varadhan L, Humphreys T, Hariman C, Walker AB, Varughese GI. GLP-1 agonist treatment: implications for diabetic retinopathy screening. Diabetes Res Clin Pract 2011;94:e68-e71. ArticlePubMed
• 38. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB. LEADER Steering Committee. LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016;375:311-322. ArticlePubMedPMC
• 39. Kumagai AK, Kang YS, Boado RJ, Pardridge WM. Upregulation of blood-brain barrier GLUT1 glucose transporter protein and mRNA in experimental chronic hypoglycemia. Diabetes 1995;44:1399-1404. ArticlePubMed
• 40. Cohen R, Pechy F, Petry T, Correa JL, Caravatto PP, Tzanno-Martins C. Bariatric and metabolic surgery and microvascular complications of type 2 diabetes mellitus. J Bras Nefrol 2015;37:399-409. ArticlePubMed
• 41. Lammert A, Hasenberg T, Kraupner C, Schnulle P, Hammes HP. Improved arteriole-to-venule ratio of retinal vessels resulting from bariatric surgery. Obesity (Silver Spring) 2012;20:2262-2267. ArticlePubMedPDF
• 42. Varadhan L, Humphreys T, Walker AB, Cheruvu CV, Varughese GI. Bariatric surgery and diabetic retinopathy: a pilot analysis. Obes Surg 2012;22:515-516. ArticlePubMedPDF
• 43. Miras AD, Chuah LL, Lascaratos G, Faruq S, Mohite AA, Shah PR, Gill M, Jackson SN, Johnston DG, Olbers T, le Roux CW. Bariatric surgery does not exacerbate and may be beneficial for the microvascular complications of type 2 diabetes. Diabetes Care 2012;35:e81ArticlePubMedPMCPDF
• 44. Johnson BL, Blackhurst DW, Latham BB, Cull DL, Bour ES, Oliver TL, Williams B, Taylor SM, Scott JD. Bariatric surgery is associated with a reduction in major macrovascular and microvascular complications in moderately to severely obese patients with type 2 diabetes mellitus. J Am Coll Surg 2013;216:545-556. ArticlePubMed
• 45. Thomas RL, Prior SL, Barry JD, Luzio SD, Eyre N, Caplin S, Stephens JW, Owens DR. Does bariatric surgery adversely impact on diabetic retinopathy in persons with morbid obesity and type 2 diabetes? A pilot study. J Diabetes Complications 2014;28:191-195. ArticlePubMed
• 46. Amin AM, Wharton H, Clarke M, Syed A, Dodson P, Tahrani AA. The impact of bariatric surgery on retinopathy in patients with type 2 diabetes: a retrospective cohort study. Surg Obes Relat Dis 2016;12:606-612. ArticlePubMed
• 47. Miras AD, Chuah LL, Khalil N, Nicotra A, Vusirikala A, Baqai N, Graham C, Ravindra S, Lascaratos G, Oliver N, le Roux CW. Type 2 diabetes mellitus and microvascular complications 1 year after Roux-en-Y gastric bypass: a case-control study. Diabetologia 2015;58:1443-1447. ArticlePubMedPMCPDF
• 48. Murphy R, Jiang Y, Booth M, Babor R, MacCormick A, Hammodat H, Beban G, Barnes RM, Vincent AL. Progression of diabetic retinopathy after bariatric surgery. Diabet Med 2015;32:1212-1220. ArticlePubMed
• 49. Kim YJ, Seo du R, Kim MJ, Lee SJ, Hur KY, Choi KS. Clinical course of diabetic retinopathy in Korean type 2 diabetes after bariatric surgery: a pilot study. Retina 2015;35:935-943. PubMed
• 50. Banks J, Adams ST, Laughlan K, Allgar V, Miller GV, Jayagopal V, Gale R, Sedman P, Leveson SH. Roux-en-Y gastric bypass could slow progression of retinopathy in type 2 diabetes: a pilot study. Obes Surg 2015;25:777-781. ArticlePubMedPDF
• 51. Brynskov T, Laugesen CS, Svenningsen AL, Floyd AK, Sorensen TL. Monitoring of diabetic retinopathy in relation to bariatric surgery: a prospective observational study. Obes Surg 2016;26:1279-1286. ArticlePubMedPDF
• 52. Singh RP, Gans R, Kashyap SR, Bedi R, Wolski K, Brethauer SA, Nissen SE, Bhatt DL, Schauer P. Effect of bariatric surgery versus intensive medical management on diabetic ophthalmic outcomes. Diabetes Care 2015;38:e32-e33. ArticlePubMedPMCPDF
• 53. Zakaria AS, Rossetti L, Cristina M, Veronelli A, Lombardi F, Saibene A, Micheletto G, Pontiroli AE. LAGB10 working group. Effects of gastric banding on glucose tolerance, cardiovascular and renal function, and diabetic complications: a 13-year study of the morbidly obese. Surg Obes Relat Dis 2016;12:587-595. ArticlePubMed
• 54. Abbatini F, Capoccia D, Casella G, Soricelli E, Leonetti F, Basso N. Long-term remission of type 2 diabetes in morbidly obese patients after sleeve gastrectomy. Surg Obes Relat Dis 2013;9:498-502. ArticlePubMed
• 55. Miras AD, le Roux CW. Metabolic surgery: shifting the focus from glycaemia and weight to end-organ health. Lancet Diabetes Endocrinol 2014;2:141-151. ArticlePubMed
• 56. Cheung D, Switzer NJ, Ehmann D, Rudnisky C, Shi X, Karmali S. The impact of bariatric surgery on diabetic retinopathy: a systematic review and meta-analysis. Obes Surg 2015;25:1604-1609. ArticlePubMedPDF
• 57. Jackson S, le Roux CW, Docherty NG. Bariatric surgery and microvascular complications of type 2 diabetes mellitus. Curr Atheroscler Rep 2014;16:453ArticlePubMedPDF

Table 1

Major studies comparing intensive medical management to conventional medical management of type 2 diabetes mellitus and the associated DR outcomes

Study	No.	Follow-up, yr	New onset DR, %	Progression of DR, %
UKPDS [23]	718	12	-	Intensive: 38.6 Conventional: 48.7 (P=0.015)
Kumamoto study [24]	110	8	Intensive: 15.4 Conventional: 47.8 (P=0.022)	Intensive: 24 Conventional: 56 (P=0.023)
ADVANCE [25]	1,241	4	Absolute incidence and progression Intensive: 14 Conventional: 16.2 (P=0.27)	-
ACCORD [26]	2,856	4	-	Intensive: 7.3 Conventional: 10.4 (P=0.003)
VADT [37]	1,791	5.6	Intensive: 42.2 Conventional: 48.9 (P=0.27)	Intensive: 17 Conventional: 22.1 (P=0.07)

DR, diabetic retinopathy; UKPDS, United Kingdom Prospective Diabetes Study; ADVANCE, Action in Diabetes and Vascular Disease Preterax and Diamicron Modified Release Controlled Evaluation; ACCORD, Action to Control Cardiovascular Risk in Diabetes; VADT, Veteran's Administration Diabetes Trial.

Table 2

Summary of studies reporting on the surgical management of type 2 diabetes mellitus and the associated DR outcomes

Study	No.	Follow-up	New onset DR	Progression of pre-existing DR	Regression of pre-existing DR	No change in DR status
Varadhan et al. (2012) [42]	22	6–12 mo	2/15 (13%)	2/7 (29%)	2/7 (29%)	16/22 (73%)
Miras et al. (2012) [43]	67	12–18 mo	0/39 (0%)	1/28 (3.6%)	5/28 (17.8%)	61/67 (91%)
Thomas et al. (2014) [45]	38	12 mo	4/26 (15%)	3/12 (25%)	5/12 (42%)	26/38 (68%)
Amin et al. (2016) [46]	S: 152 M: 155	3 yr	29/106 (27%)	5/41 (12%)	5/41 (12%)	113/152 (74%)
Miras et al. (2015) [47]	S: 56 M: 21	1 yr	S and M: 0/77 (0%)	S: 6/56 (11%) M: 3/21 (14%)	S: 6/56 (11%) M: 1/21 (5%)	S: 44/56 (78%) M: 17/21 (81%)
Murphy et al. (2015) [48]	0318	334 day	38/218 (17%)	12/100 (12%)	35/100 (35%)	232/318 (73%)
Kim et al. (2015) [49]	20	12 mo	2/12 (16.6%)	7/8 (87.5%)	1/8 (12.5%)	10/12 (83.3%)
Banks et al. (2015) [50]	S: 21 M: 24	2 yr	Surgery: mean deterioration of 0.24 grades (P=0.135) Controls: mean deterioration of 0.38 grades (P=0.026)
Zakaria et al. (2016) [53]	S: 21 M: 24	13 yr	Surgery: 0/20 (0%) Controls: 1/20 (5%)	-	-	Surgery: 1/1 (100%) Controls: 4/4 (100%)
Abbatini et al. (2013) [54]	33	3 or 5 yr	No new incidences of DR (32/32)	-	-	NPDR: 1/1 (100%)
Brynskov et al. (2016) [51]	56	1, 3, 6, and 12 mo	12 mo: 0/32 (0%) At 6 mo: 1/32 (3%)	12 mo: 3/24 (13%) 5/24 (21%) at any follow-up visit	12 mo: 4/24 (17%) 6/24 (25%) at any visit	12 mo: 49/56 (87.5%)
Singh et al. (2015) [52]	150	2 yr	No difference between bariatric surgery and intensive medical management			86.5% of all participants (n=150)
Johnson et al. (2013) [44]	15,951	20 mo	Surgery vs. Controls Diagnosis of blindness: <0.1% vs. 0.3% Laser eye/retinal surgery required: 0.2% vs. 0.6%

DR, diabetic retinopathy; S, surgical; M, medical; NPDR, non-proliferative diabetic retinopathy.

Table 3

Summary of DR status at baseline and the associated retinal outcomes after bariatric surgery

Preoperative DR status	Deteriorated	Stable	Improved
No retinopathy (n=443)
Thomas et al. (2014) [45]	4/26	22/26
Amin et al. (2016) [46]	29/106	77/106
Murphy et al. (2015) [48]	38/218	180/218
Kim et al. (2015) [49]	2/12	10/12
Zakaria et al. (2016) [53]	0/20	20/20
Abbatini et al. (2013) [54]	0/32	32/32
Brynskov et al. (2016) [51]	0/29	29/29
Total no. (%)	73/443 (16.5)	370/443 (83.5)
Non-proliferative retinopathy (n=179)
Thomas et al. (2014) [45]	1/10	4/10	5/10
Amin et al. (2016) [46]	5/42	32/42	5/42
Murphy et al. (2015) [48]	12/99	52/99	35/99
Kim et al. (2015) [49]	5/6	1/6	0/6
Zakaria et al. (2016) [53]	0/1	1/1	0/1
Abbatini et al. (2013) [54]	0/1	1/1	0/1
Brynskov et al. (2016) [51]	2/20	15/20	3/20
Total no. (%)	25/179 (14.0)	106/179 (59.2)	48/179 (26.8)
Proliferative (n=12)
Thomas et al. (2014) [45]	2/2	0/2	0/2
Amin et al. (2016) [46]	0/4	4/4	0/4
Murphy et al. (2015) [48]	0/1	1/1	0/1
Kim et al. (2015) [49]	2/2	0/2	0/2
Zakaria et al. (2016) [53]	0/0	0/0	0/0
Abbatini et al. (2013) [54]	0/0	0/0	0/0
Brynskov et al. (2016) [51]	1/3	1/3	1/3
Total no. (%)	5/12 (41.6)	6/12 (50)	1/12 (8.3)

DR, diabetic retinopathy.

Figure & Data

References

Citations

Citations to this article as recorded by  

• Author response to: remission of diabetes mellitus after bariatric surgery: the putative link with worsening diabetic retinopathy and a need for ongoing postoperative follow-up retinal screening
  Karl Hage, Omar M. Ghanem
  Surgery for Obesity and Related Diseases.2024; 20(5): 499.     CrossRef
• Impact of Bariatric Surgery on Treatment Burden and Progression of Diabetic Retinopathy
  Ariana Allen, Hemal Patel, Sandra S. Stinnett, Jullia A. Rosdahl, Stefanie Schuman
  Journal of VitreoRetinal Diseases.2024; 8(3): 263.     CrossRef
• Role of Systemic Factors in Improving the Prognosis of Diabetic Retinal Disease and Predicting Response to Diabetic Retinopathy Treatment
  Joe Mellor, Anita Jeyam, Joline W.J. Beulens, Sanjeeb Bhandari, Geoffrey Broadhead, Emily Chew, Ward Fickweiler, Amber van der Heijden, Daniel Gordin, Rafael Simó, Janet Snell-Bergeon, Anniina Tynjälä, Helen Colhoun
  Ophthalmology Science.2024; 4(4): 100494.     CrossRef
• The Importance of Glycaemic Control Before Bariatric Surgery: Preventing Microvascular and Metabolic Complications
  Adhithya Sankar, Rajshekhar N. Mudaliar, Rupinder S. Kochhar, Lucinda K. M. Summers, Akheel A. Syed, Waseem Majeed
  Obesity Surgery.2024; 34(6): 2248.     CrossRef
• Rapid Reduction of HbA1c and Early Worsening of Diabetic Retinopathy: A Real-world Population-Based Study in Subjects With Type 2 Diabetes
  Rafael Simó, Josep Franch-Nadal, Bogdan Vlacho, Jordi Real, Ester Amado, Juana Flores, Manel Mata-Cases, Emilio Ortega, Mercedes Rigla, Joan-Anton Vallés, Cristina Hernández, Didac Mauricio
  Diabetes Care.2023; 46(9): 1633.     CrossRef
• Early microvascular complications in type 1 and type 2 diabetes: recent developments and updates
  Kalie L. Tommerdahl, Allison L. B. Shapiro, Edward J. Nehus, Petter Bjornstad
  Pediatric Nephrology.2022; 37(1): 79.     CrossRef
• New Insights into Treating Early and Advanced Stage Diabetic Retinopathy
  Rafael Simó, Cristina Hernández
  International Journal of Molecular Sciences.2022; 23(15): 8513.     CrossRef
• Response to Letter to the Editor Concerning: Adam S. et al. Improvements in Diabetic Neuropathy and Nephropathy After Bariatric Surgery: a Prospective Cohort Study
  Safwaan Adam, Jan Hoong Ho, Akheel A. Syed, Rayaz A. Malik, Handrean Soran
  Obesity Surgery.2022; 32(10): 3460.     CrossRef
• Weight management and multi-morbidity
  Carrie Ashby
  InnovAiT: Education and inspiration for general practice.2021; 14(8): 523.     CrossRef
• The Safety of Pharmacological and Surgical Treatment of Diabetes in Patients with Diabetic Retinopathy—A Review
  Wojciech Matuszewski, Angelika Baranowska-Jurkun, Magdalena Maria Stefanowicz-Rutkowska, Katarzyna Gontarz-Nowak, Ewa Gątarska, Elżbieta Bandurska-Stankiewicz
  Journal of Clinical Medicine.2021; 10(4): 705.     CrossRef
• Safety of Semaglutide
  Mark M. Smits, Daniël H. Van Raalte
  Frontiers in Endocrinology.2021;[Epub]     CrossRef
• Outcomes of Diabetic Retinopathy Post-Bariatric Surgery in Patients with Type 2 Diabetes Mellitus
  Ana Maria Dascalu, Anca Pantea Stoian, Alina Popa Cherecheanu, Dragos Serban, Daniel Ovidiu Costea, Mihail Silviu Tudosie, Daniela Stana, Denisa Tanasescu, Alexandru Dan Sabau, Gabriel Andrei Gangura, Andreea Cristina Costea, Vanessa Andrada Nicolae, Cata
  Journal of Clinical Medicine.2021; 10(16): 3736.     CrossRef
• Future perspectives in diabesity treatment: Semaglutide, a glucagon‑like peptide 1 receptor agonist (Review)
  Mariana Tilinca, Robert Tiuca, Cristina Niculas, Andreea Varga, Ioan Tilea
  Experimental and Therapeutic Medicine.2021;[Epub]     CrossRef
• Safety of injectable semaglutide for type 2 diabetes
  Rajesh Peter, Steve C. Bain
  Expert Opinion on Drug Safety.2020; 19(7): 785.     CrossRef
• Early worsening of diabetic retinopathy due to intensive glycaemic control
  Shueh Wen Lim, Peter van Wijngaarden, Colin A. Harper, Salmaan H. Al‐Qureshi
  Clinical & Experimental Ophthalmology.2019; 47(2): 265.     CrossRef
• Worsening of diabetic retinopathy with rapid improvement in systemic glucose control: A review
  Stephen C. Bain, Michael A. Klufas, Allen Ho, David R. Matthews
  Diabetes, Obesity and Metabolism.2019; 21(3): 454.     CrossRef
• Diabetische Retinopathie bei Patienten mit Diabetes mellitus
  Olga Simó-Servat, Cristina Hernández, Rafael Simó
  Kompass Ophthalmologie.2019; 5(4): 157.     CrossRef
• Diabetic Retinopathy in the Context of Patients with Diabetes
  Olga Simó-Servat, Cristina Hernández, Rafael Simó
  Ophthalmic Research.2019; 62(4): 211.     CrossRef
• MANAGEMENT OF ENDOCRINE DISEASE: Which metabolic procedure? Comparing outcomes in sleeve gastrectomy and Roux-en Y gastric bypass
  Adrian T Billeter, Javier R de la Garza Herrera, Katharina M Scheurlen, Felix Nickel, Franck Billmann, Beat P Müller-Stich
  European Journal of Endocrinology.2018; 179(2): R77.     CrossRef
• Aggravation précoce de la rétinopathie diabétique lors de l’optimisation du contrôle glycémique
  S. Feldman-Billard
  Médecine des Maladies Métaboliques.2018; 12(7): 560.     CrossRef
• Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy
  Tina Vilsbøll, Stephen C. Bain, Lawrence A. Leiter, Ildiko Lingvay, David Matthews, Rafael Simó, Ida Carøe Helmark, Nelun Wijayasinghe, Michael Larsen
  Diabetes, Obesity and Metabolism.2018; 20(4): 889.     CrossRef
• Glucagon-Like Peptide 1 Receptor Agonists and the Risk of Incident Diabetic Retinopathy
  Antonios Douros, Kristian B. Filion, Hui Yin, Oriana Hoi Yu, Mahyar Etminan, Jacob A. Udell, Laurent Azoulay
  Diabetes Care.2018; 41(11): 2330.     CrossRef
• Early worsening of diabetic retinopathy after rapid improvement of blood glucose control in patients with diabetes
  S. Feldman-Billard, É. Larger, P. Massin
  Diabetes & Metabolism.2018; 44(1): 4.     CrossRef
• Excess visceral adiposity is associated with diabetic retinopathy in a multiethnic Asian cohort with longstanding type 2 diabetes
  Angela Moh, Kumari Neelam, Xiao Zhang, Chee Fang Sum, Subramaniam Tavintharan, Keven Ang, Simon Biing Ming Lee, Wern Ee Tang, Su Chi Lim
  Endocrine Research.2018; 43(3): 186.     CrossRef
• GLP-1R as a Target for the Treatment of Diabetic Retinopathy: Friend or Foe?
  Rafael Simó, Cristina Hernández
  Diabetes.2017; 66(6): 1453.     CrossRef
• The Long-Term Effects of Bariatric Surgery on Type 2 Diabetes Remission, Microvascular and Macrovascular Complications, and Mortality: a Systematic Review and Meta-Analysis
  Binwu Sheng, Khoa Truong, Hugh Spitler, Lu Zhang, Xuetao Tong, Liwei Chen
  Obesity Surgery.2017; 27(10): 2724.     CrossRef
• Bariatric Surgery for Adolescents with Type 2 Diabetes: an Emerging Therapeutic Strategy
  M. A. Stefater, T. H. Inge
  Current Diabetes Reports.2017;[Epub]     CrossRef
• The role of bariatric surgery to treat diabetes: current challenges and perspectives
  Chrysi Koliaki, Stavros Liatis, Carel W. le Roux, Alexander Kokkinos
  BMC Endocrine Disorders.2017;[Epub]     CrossRef

About this article

Gorman DM, le Roux CW, Docherty NG. The Effect of Bariatric Surgery on Diabetic Retinopathy: Good, Bad, or Both?. Diabetes Metab J. 2016;40(5):354-364.

Received: Jun 15, 2016; Accepted: Aug 01, 2016

DOI: https://doi.org/10.4093/dmj.2016.40.5.354.

Download citation ↓